Boston Scientific (BSX) Receives a Hold from Leerink Partners

In a report released today, Danielle Antalffy from Leerink Partners maintained a Hold rating on Boston Scientific (BSXResearch Report), with a price target of $48.00. The company’s shares closed last Wednesday at $43.06.

According to, Antalffy is a 4-star analyst with an average return of 6.3% and a 46.3% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $50.50, representing a 16.0% upside. In a report released yesterday, Needham also maintained a Hold rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Based on Boston Scientific’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.13 billion and net profit of $95 million. In comparison, last year the company earned revenue of $2.71 billion and had a net profit of $210 million.

Based on the recent corporate insider activity of 172 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Boston Scientific Corporation engages in the manufacturing of medical devices and products that are used in various interventional medical specialties worldwide. The company provides implantable devices including heart monitors, technologies for treating coronary artery disease and other cardiovascular disorders, and devices for diagnosing and treating gastrointestinal and pulmonary problems.

Read More on BSX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed